Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.

Jessica B DiSilvestro,Jessica Haddad,Katina Robison,Lindsey Beffa,Jessica Laprise,Jennifer Scalia-Wilbur,Christina Raker,Melissa Clark,Elizabeth Lokich,Erin Hofstatter,Disha Dalela,Amy Brown,Leslie Bradford,Maris Toland,Ashley Stuckey

Menopause (New York, N.Y.)（2023）

Cited 0|Views15

No score

Abstract

BRCA mutation carriers frequently undergo prophylactic BSO at young ages, and less than half report using HT. This study highlights barriers to HT use, such as patient fears and physician discouragement, and identifies potential areas to improve educational efforts.

Translated text

Key words

BRCA, Hormone therapy, Physician counseling, Risk reducing

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined